Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SCLX

Scilex Holding Company

Apr 19 • 02:44PM ET

0.8801

Dollar change -0.0199
Percentage change -2.22	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VTI VXF VXF IWM LABU IWN VHT VTWO IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.87	Insider Own	38.09%	Shs Outstand	166.19M	Perf Week	-33.83%
Market Cap	146.26M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	0.00%	Shs Float	102.88M	Perf Month	-35.29%
Income	-114.33M	PEG	-	EPS next Q	-0.17	Inst Own	15.92%	Short Float	6.40%	Perf Quarter	-40.94%
Sales	46.74M	P/S	3.13	EPS this Y	41.76%	Inst Trans	-9.17%	Short Ratio	6.80	Perf Half Y	-47.62%
Book/sh	-1.73	P/B	-	EPS next Y	36.84%	ROA	-121.73%	Short Interest	6.58M	Perf Year	-93.81%
Cash/sh	0.02	P/C	37.31	EPS next 5Y	-	ROE	-163.31%	52W Range	0.85 - 14.64	Perf YTD	-56.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-93.99%	Beta	0.92
Dividend TTM	-	Quick Ratio	0.17	Sales past 5Y	14.78%	Gross Margin	57.58%	52W Low	3.11%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	-386.34%	Oper. Margin	-225.55%	RSI (14)	21.67	Volatility	13.93% 9.47%
Employees	105	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-244.59%	Recom	1.00	Target Price	6.83
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-0.28%	Payout	-	Rel Volume	1.81	Prev Close	0.90
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	967.36K	Price	0.88
SMA20	-37.05%	SMA50	-42.36%	SMA200	-61.31%	Trades		Volume	1,428,713	Change	-2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-23	Initiated	B. Riley Securities	Buy	$4
Oct-13-23	Initiated	B. Riley Securities	Buy	$4
Oct-09-23	Initiated	H.C. Wainwright	Buy	$12

Apr-16-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses (GlobeNewswire) -9.38%
Apr-09-24 09:00AM	Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool (GlobeNewswire)
Mar-27-24 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend (GlobeNewswire) +6.62%
Mar-21-24 09:30AM	Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients (GlobeNewswire)
Mar-20-24 11:00AM	Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed (GlobeNewswire)
09:00AM	Loading…
09:00AM	Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba (GlobeNewswire)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-18-24 09:00AM	Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire)
Mar-15-24 02:45PM	Scilex Holding Announces Issuance of Halal Certification for its ZTlido product by Circle H International, Inc. (GlobeNewswire)
09:00AM	Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement (GlobeNewswire)
Mar-05-24 04:01PM	Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering (GlobeNewswire)
09:00AM	Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba , its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024 (GlobeNewswire)
Mar-04-24 09:00AM	Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates (GlobeNewswire)
Mar-02-24 03:25PM	Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024 (GlobeNewswire)
Feb-29-24 05:32PM	Scilex Holding Company Announces $10 Million Bought Deal Offering (GlobeNewswire) -6.20%
09:00AM	Loading…
Feb-28-24 09:00AM	Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA in Most of Their Stores Throughout the U.S. (GlobeNewswire)
Feb-27-24 09:00AM	Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM) (GlobeNewswire) +11.59%
Feb-26-24 04:53PM	Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement (GlobeNewswire) +18.29%
09:00AM	Scilex Holding Company Announces that ZTlido Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met (GlobeNewswire)
Feb-20-24 09:00AM	Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido for the Treatment of Chronic Neck Pain (GlobeNewswire)
Jan-08-24 09:00AM	Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024 (GlobeNewswire)
Jan-02-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information (GlobeNewswire)
Dec-26-23 11:00AM	Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire) +15.71%
Dec-20-23 09:00AM	Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists (GlobeNewswire) -7.14%
Dec-19-23 09:00AM	Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba as a Liquid Colchicine Formulation Designed for Precision Dosing (GlobeNewswire) +11.11%
Dec-15-23 09:00AM	Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB in most of their stores throughout the U.S. (GlobeNewswire) +8.59%
Dec-12-23 09:00AM	Scilex Holding Company Announces Expanded Access to ELYXYB By the Execution of First ELYXYB Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population (GlobeNewswire)
Dec-06-23 09:00AM	Scilex Holding Company announces that ZTlido (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State (GlobeNewswire)
Dec-04-23 09:00AM	Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee (GlobeNewswire)
09:00AM	Scilex Holding Company announces the addition of ZTlido (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List of the State of Tennessee (GlobeNewswire)
09:00AM	Loading…
Dec-01-23 09:00AM	Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information (GlobeNewswire) +8.00%
Nov-30-23 09:00AM	Scilex Holding Company announces successful FDA audit of enhanced ZTlido manufacturing facility in Japan (GlobeNewswire) -10.71%
Nov-28-23 09:00AM	Scilex Holding Company announces pharmacy initiative to stock ELYXYB in over 500 stores for a leading pharmacy chain in the U.S. (GlobeNewswire) -6.25%
Nov-27-23 09:00AM	Scilex Holding Company announces completion of commercial manufacturing of Gloperba with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 (GlobeNewswire) +13.39%
Nov-22-23 09:00AM	Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy (GlobeNewswire) +6.59%
Nov-21-23 09:00AM	Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB (GlobeNewswire) -13.85%
Nov-17-23 09:00AM	Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch (GlobeNewswire)
Nov-15-23 09:00AM	Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch (GlobeNewswire)
Nov-02-23 09:00AM	Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica) (GlobeNewswire)
09:00AM	Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido , in Treatment of Musculoskeletal Pain Disorders (GlobeNewswire)
Nov-01-23 09:00AM	Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information (GlobeNewswire)
Oct-27-23 03:38PM	UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure (GlobeNewswire)
02:05PM	Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure (GlobeNewswire)
Oct-26-23 06:12AM	SCLX: An Innovative and Growing Pain Management Company (Zacks) -5.42%
Oct-09-23 02:55PM	Why Shares of Scilex Are Up Monday (Motley Fool) +15.92%
Oct-07-23 07:27PM	Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price (GlobeNewswire)
Oct-04-23 12:59PM	Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company (GlobeNewswire) +11.90%
Oct-03-23 09:00AM	Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company (GlobeNewswire) -5.26%
Sep-27-23 09:00AM	Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401) (GlobeNewswire)
Sep-25-23 09:00AM	Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 (GlobeNewswire)
Sep-22-23 11:38AM	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company (PR Newswire) -9.71%
Sep-21-23 04:05PM	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. (GlobeNewswire)
Sep-14-23 09:00AM	Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP) (GlobeNewswire)
Sep-13-23 09:00AM	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder (GlobeNewswire) -8.61%
Sep-12-23 05:34PM	Sorrento Stock Deal Emerges Days Before It Runs Out of Cash (Bloomberg)
09:00AM	Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV (GlobeNewswire)
09:00AM	Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV (GlobeNewswire)
Sep-11-23 09:00AM	Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information (GlobeNewswire) -5.12%
Jul-27-23 09:00AM	Sorrento Issues a FAQ in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders (GlobeNewswire)
Jul-21-23 05:53PM	/C O R R E C T I O N -- Sorrento Therapeutics, Inc./ (PR Newswire) -5.08%
Jul-20-23 09:00AM	Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders (PR Newswire)
Jul-13-23 09:00AM	Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido® (GlobeNewswire) +10.22%
Jul-05-23 09:00AM	Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based On Currently Available Information (GlobeNewswire)
Jun-16-23 09:00AM	Scilex Holding Company to Present Data on ELYXYB (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX. (GlobeNewswire)
Jun-15-23 09:03AM	Scilex Holding Company Announces that Sorrento Therapeutics, Inc.s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock (GlobeNewswire)
09:00AM	Sorrento Therapeutics, Inc.'s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock (PR Newswire)
Jun-01-23 12:28PM	Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information (GlobeNewswire)
May-31-23 03:16PM	Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (CHT or Territories Distributor) and Farouk, Maamoun Tamer & Co. (Master Distributor) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia (GlobeNewswire)
May-22-23 09:00AM	Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023 (GlobeNewswire) +9.80%
May-14-23 03:00PM	Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts (PR Newswire)
08:09AM	Scilex Holding First Quarter 2023 Earnings: US$0.22 loss per share (vs US$0.046 loss in 1Q 2022) (Simply Wall St.)
May-05-23 06:08AM	Why Investors Shouldn't Be Surprised By Scilex Holding Company's (NASDAQ:SCLX) 34% Share Price Plunge (Simply Wall St.)
May-04-23 09:00AM	Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (GlobeNewswire)
Apr-28-23 02:42PM	Why Shares of Scilex Slumped This Week (Motley Fool) -6.46%
09:00AM	Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023 (GlobeNewswire)
Apr-27-23 07:26AM	Scilex Holding Company's (NASDAQ:SCLX) last week's 47% decline must have disappointed retail investors who have a significant stake (Simply Wall St.)
Apr-25-23 07:30PM	Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrentos Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend (GlobeNewswire) -6.47%
Apr-17-23 09:00AM	Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region (GlobeNewswire) +6.84%
Apr-14-23 06:32PM	Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders (GlobeNewswire)
Apr-13-23 12:25PM	Bankrupt Drugmaker Sorrentos Scilex Unit Explores Stock Sale (The Wall Street Journal) -8.04%
Apr-05-23 05:27PM	Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders (GlobeNewswire) +56.57%
Apr-04-23 01:49PM	Sorrento Therapeutics, Inc.'s Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock (PR Newswire)
Mar-27-23 09:00AM	Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued FAQ Regarding the Dividend of Scilex Holding Company Common Stock (GlobeNewswire)
Mar-21-23 09:00AM	Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products (GlobeNewswire)
Mar-08-23 10:13AM	Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment (GlobeNewswire) -9.14%
Feb-27-23 09:00AM	Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management (GlobeNewswire)
Feb-18-23 08:37PM	Sorrento Posts Form 8937 to Supplement its Previously Issued FAQ Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, Scilex) (GlobeNewswire)
Feb-17-23 03:47PM	Sorrento Issues Update to its Previously Issued FAQ Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, Scilex) (GlobeNewswire)
Feb-16-23 02:40PM	Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions (PR Newswire) -9.07%
Feb-13-23 03:46PM	Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Todays Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc. (GlobeNewswire) -26.33%
Feb-04-23 10:48PM	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders (GlobeNewswire)
Feb-03-23 08:59PM	Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock (GlobeNewswire)
Feb-02-23 01:15PM	Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued FAQ Regarding the Dividend of Scilex Holding Company Common Stock (GlobeNewswire) +11.43%
Jan-20-23 10:24AM	Why Shares of Scilex Soared This Week (Motley Fool) +6.59%

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCLX

Scilex Holding Company

Upgrade your FINVIZ experience